Wockhardt
 |
|
| Type | Public (NSE: WOCKPHARMA) |
|---|---|
| Industry | Pharmaceuticals Health care |
| Founded | 1960s |
| Founder(s) | Habil Khorakiwala |
| Headquarters | Mumbai, India |
| Area served | Worldwide |
| Key people | Habil Khorakiwala (Chairman) Murtaza Khorakiwala (Managing Director) Huzaifa Khorakiwala (Executive Director) |
| Products | Formulations Biopharmaceuticals Nutrition products Vaccines |
| Revenue |   3,600 crore (US$720 million)[1] |
| Employees | 7,000 (2009) |
| Website | www.wockhardt.com |
Wockhardt Ltd. is a pharmaceutical and biotechnology company headquartered in Mumbai, India. The company has manufacturing plants in India, UK, Ireland, France and US, and subsidiaries in US, UK, Ireland and France. It is a global company with a more than half of its revenue coming from Europe.[2] The Company has a market capitalisation of over 4,800 crore (US$960 million) and an annual turnover of 3,600 crore (US$720 million). It produces formulations, biopharmaceuticals, nutrition products, vaccines and active pharmaceutical ingredients (APIs).[3] The company employs over 7,000 people globally.[4] Wockhardt Hospitals is a subsidiary of the Wockhardt Group.[5]
Wockhardt was founded by Habil Khorakiwala in the early 1960s. [4] His father Fakhruddin T. Khorakiwala had acquired Worli Chemical Works [6] in 1959. This was incorporated as Wockhardt Pvt. Ltd., in 1973.[2] Wockhardt Ltd. was incorporated on July 8.1999.[7] Wockhardt is often confused as a multinational because of its German sounding name.[8]
Wockhardt is the first company outside of the US and Europe to manufacture recombinant human insulin.[9]
Wockhardt's acquisitions include Wallis Laboratory, UK (1998), Merind, India (1998), CP Pharmaceuticals, UK (2003), Espharma GmbH, Germany (2004), Dumex India (2006), Pinewood Laboratory, Ireland (2006) and Negma, France (2007).[2] Wockhardt's debt following the acquisitions was close to Rs 3,800 crore, and Habil Khorakiwala quit as Managing Director.[10] The board of directors, on March 31, 2009 approved the appointments of Habil Khorakiwala's sons Murtaza Khorakiwala and Hozaifa Khorakiwala as Managing Director and Executive Director respectively.[11]
[edit] References
- ^ "Wockhardt". Wockhardt. http://www.wockhardt.com/finacials_investor.html. Retrieved 2010-07-16.
- ^ a b c Sanju Verma, Amit Shah (2007). "Wockhardt : "Wock"ing the talk...". HDFC securities. India Research. http://birlaa.com/wp-filez/Wockhardt%20Company%20Report.pdf.
- ^ "ABOUT US - Who We Are". http://www.wockhardt.com/about_us.html.
- ^ a b "ABOUT US - Chairman's Profile". http://www.wockhardt.com/c_profile.html.
- ^ "OUR OTHER WEBSITES". http://www.wockhardt.com/web_sites.html.
- ^ Priyanka Sangani (March 28, 2008). "Marginal business logic". The Economic Times. http://economictimes.indiatimes.com/Corporate_Dossier/Marginal_business_logic/articleshow/2905713.cms.
- ^ "Wockhardt Limited". http://www.pharmabiz.com/redfr.asp?fn=/comprof/wockhardt.asp. Retrieved 2009-05-09.
- ^ T. Surendar, Charles Assisi (January 19, 2008). "'We need a Nano for medicines too'". The Times of India. http://timesofindia.indiatimes.com/articleshow/msid-2712332,prtpage-1.cms.
- ^ "Introducing Wockhardt". http://www.wockhardt.co.uk/aboutus/wockhardtinternational.asp. Retrieved 2009-05-09.
- ^ Shobhana Subramanian (April 3, 2009). "Newsmaker: Habil F Khorakiwala, Scientist in a hurry". Business Standard. http://www.business-standard.com/india/news/newsmaker-habil-f-khorakiwala/353842/.
- ^ "Murtaza Khorakiwala is new MD of Wockhardt, Hozaifa new Executive Director". DWS Pill Scribe. April 2, 2009. http://www.dancewithshadows.com/pillscribe/murtaza-khorakiwala-is-new-md-of-wockhardt-hozaifa-new-executive-director/.
